{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:12:30Z","timestamp":1777104750600,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"am","delay-in-days":302,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS-078555"],"award-info":[{"award-number":["NS-078555"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002385","name":"Ministry of Higher Education","doi-asserted-by":"publisher","award":["JS-3725"],"award-info":[{"award-number":["JS-3725"]}],"id":[{"id":"10.13039\/501100002385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.msard.2019.02.023","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T12:55:16Z","timestamp":1550926516000},"page":"231-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2380-8152","authenticated-orcid":false,"given":"Sara","family":"Salama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7969-8346","authenticated-orcid":false,"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.msard.2019.02.023_bib0001","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2019.02.023_bib0002","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1352458515587751","article-title":"Clinical and MRI phenotype of children with MOG antibodies","volume":"22","author":"Fernandez-Carbonell","year":"2016","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2019.02.023_bib0003","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1212\/WNL.0000000000004117","article-title":"Diagnostic algorithm for relapsing acquired demyelinating syndromes in children","volume":"89","author":"Hacohen","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2019.02.023_bib0004","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein igg disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.msard.2019.02.023_bib0005","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"Hoftberger","year":"2015","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2019.02.023_bib0006","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","article-title":"Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases","volume":"88","author":"Hyun","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2019.02.023_bib0007","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflam."},{"issue":"3","key":"10.1016\/j.msard.2019.02.023_bib0008","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.msard.2019.02.023_bib0009","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2019.02.023_bib0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/jnnp-2016-314005","article-title":"Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease","volume":"88","author":"Jurynczyk","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.msard.2019.02.023_bib0011","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/1352458514566666","article-title":"Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort","volume":"21","author":"Ketelslegers","year":"2015","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.msard.2019.02.023_bib0012","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol."},{"issue":"6","key":"10.1016\/j.msard.2019.02.023_bib0013","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurology(R) Neuroimmunol. Neuroinflam."},{"issue":"11","key":"10.1016\/j.msard.2019.02.023_bib0014","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2013.3890","article-title":"Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies","volume":"70","author":"Kitley","year":"2013","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.msard.2019.02.023_bib0015","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamaneurol.2014.940","article-title":"Features of neuromyelitis optica spectrum disorders and aquaporin-4 with myelin-oligodendrocyte glycoprotein antibodies-reply","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2019.02.023_bib0016","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/jnnp-2014-308723","article-title":"MOG-IgG serological status matters in paediatric ADEM","volume":"86","author":"Misu","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.msard.2019.02.023_bib0017","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders","volume":"23","author":"Montcuquet","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2019.02.023_bib0018","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2019.02.023_bib0019","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"issue":"1","key":"10.1016\/j.msard.2019.02.023_bib0020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J. Neuroinflam."},{"key":"10.1016\/j.msard.2019.02.023_bib0021","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.msard.2018.07.026","article-title":"Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: an ethnicity influence?","volume":"25","author":"Papais-Alvarenga","year":"2018","journal-title":"Mult. Sclerosis Related Disord."},{"issue":"5","key":"10.1016\/j.msard.2019.02.023_bib0022","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-1958","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody Persistency in a Steroid-Dependent ADEM Case","volume":"137","author":"Polat","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.msard.2019.02.023_bib0023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2019.02.023_bib0024","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol(R) Neuroimmunol. Neuroinflam."},{"issue":"3","key":"10.1016\/j.msard.2019.02.023_bib0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WCO.0000000000000446","article-title":"Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they?","volume":"30","author":"Reindl","year":"2017","journal-title":"Curr. Opin. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2019.02.023_bib0026","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2019.02.023_bib0027","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1212\/NXI.0000000000000225","article-title":"Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus","volume":"3","author":"Sepulveda","year":"2016","journal-title":"Neurology(R) Neuroimmunol. Neuroinflam."},{"issue":"5","key":"10.1016\/j.msard.2019.02.023_bib0028","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1212\/NXI.0000000000000257","article-title":"Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis","volume":"3","author":"Spadaro","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2019.02.023_bib0029","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ene.12898","article-title":"Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands","volume":"23","author":"van Pelt","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2019.02.023_bib0030","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurology(R) Neuroimmunol. Neuroinflam."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819301002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819301002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:44:50Z","timestamp":1761900290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819301002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":30,"alternative-id":["S2211034819301002"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.02.023","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}